You're managing over a hundred SLRs annually. The bottleneck isn't capability, it's the volume of citations multiplied by the irreducible time cost of human review.
The market reality: European market authorization to reimbursement averages 881 days—71% after regulatory filing. Every month your SLR is delayed erodes patent exclusivity.
The quality paradox:
The math: Compress six major SLRs by 10 months each—that's 5 years of HTA timeline acceleration, potentially worth billions in captured revenue.
Conduct 2-3× more studies with the same team.